Nisa Investment Advisors LLC Sells 190 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Nisa Investment Advisors LLC lessened its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 25.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 544 shares of the medical research company’s stock after selling 190 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Bio-Rad Laboratories were worth $176,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. ING Groep NV bought a new stake in Bio-Rad Laboratories in the third quarter worth $44,000. Pacific Center for Financial Services bought a new stake in Bio-Rad Laboratories in the first quarter worth $49,000. Atlas Capital Advisors LLC bought a new stake in Bio-Rad Laboratories in the second quarter worth $50,000. Dark Forest Capital Management LP lifted its stake in Bio-Rad Laboratories by 1,160.0% in the first quarter. Dark Forest Capital Management LP now owns 126 shares of the medical research company’s stock worth $60,000 after purchasing an additional 116 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Bio-Rad Laboratories by 39.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 163 shares of the medical research company’s stock worth $68,000 after purchasing an additional 46 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Insider Buying and Selling

In related news, EVP Michael Crowley sold 3,000 shares of the stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total value of $1,008,000.00. Following the completion of the transaction, the executive vice president now directly owns 6,942 shares of the company’s stock, valued at $2,332,512. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 17.06% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms have weighed in on BIO. UBS Group boosted their price target on shares of Bio-Rad Laboratories from $395.00 to $420.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. StockNews.com downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. Citigroup downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $400.00 to $365.00 in a research note on Wednesday, April 3rd. Finally, Royal Bank of Canada lowered their price objective on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a research note on Friday, February 16th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $468.00.

Bio-Rad Laboratories Stock Performance

Shares of NYSE:BIO opened at $279.73 on Friday. The company has a market cap of $7.98 billion, a price-to-earnings ratio of -13.02 and a beta of 0.87. The company has a 50-day moving average price of $329.85 and a 200-day moving average price of $320.23. The company has a current ratio of 5.83, a quick ratio of 4.34 and a debt-to-equity ratio of 0.14. Bio-Rad Laboratories, Inc. has a 12 month low of $261.59 and a 12 month high of $473.76.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, February 15th. The medical research company reported $3.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.93 by $0.17. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%. The company had revenue of $681.18 million during the quarter, compared to the consensus estimate of $685.00 million. During the same period in the prior year, the firm earned $3.31 earnings per share. Bio-Rad Laboratories’s revenue was down 6.7% on a year-over-year basis. As a group, equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.